Keybanc analyst Kenneth Zener upgrades KB Home (NYSE:KBH) from Underweight to Sector Weight.
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Lowers Price Target to $33
HC Wainwright & Co. analyst Douglas Tsao maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and lowers the price target from $50 to $33.